

COPY OF PAPERS
ORIGINALLY FILED

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/738,046	12/15/2000	Philip L. Felgner	GTSYS.004A

CONFIRMATION NO. 2320

20995
KNOBBE MARTENS OLSON & BEAR LLP
620 NEWPORT CENTER DRIVE
SIXTEENTH FLOOR
NEWPORT BEACH, CA 92660

FORMALITIES LETTER

RECEIVED

REC



OC000000007520705

APR 26 2002

MAY 06 2002

Technology Center 2600

TECH CENTER 1600/2900

Date Mailed: 02/22/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



05 20
COPY OF PAPERS
ORIGINALLY FILED

0380
PATENT

Case Docket No. GTSYS.004A 2651

Date: April 19, 2002

Page 1

In re application of : Felgner, et al.
App. No. : 09/738,046
Filed : December 15, 2000
For : INTRACELLULAR PROTEIN
DELIVERY COMPOSITIONS
AND METHODS OF USE
Examiner : Unknown
Art Unit : 2651

) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first class mail in
) an envelope addressed to: United States Patent
) and Trademark Office, P.O. 2327, Arlington, VA
) 22202, on

April 19, 2002

(Date)

Ned A. Israelsen, Reg. No. 29,655

MAY 06 2002

UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 2327
Arlington, VA 22202

RECEIVED
TECH CENTER 1600/2900
APR 26 2002

Sir:

Transmitted herewith is an Amendment and Response to Written Communication in the above-identified application.

Technology Center 2600

The fee has been calculated as shown below:

CLAIMS AS FILED									
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA		RATE		ADDITIONAL FEE
Total Claims	27	—	27	=	0	x	\$9	=	\$0
Independent Claims	2	—	3	=	0	x	\$42	=	\$0
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT									\$0

- (X) The present application qualifies for small entity status under 37 C.F.R. § 1.27.
- (X) Copy of Notice to Comply.
- (X) Sequence Submission Statement.
- (X) Sequence Listing in 1 page.
- (X) Sequence Listing in CRF pursuant to 37 C.F.R. § 1.821(e).
- (X) Return prepaid postcard.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Ned A. Israelsen
Registration No. 29,655
Attorney of Record
Customer No. 20,995

#8



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Felgner, et al.
Appl. No. : 09/738,046
Filed : December 15, 2000
For : INTRACELLULAR PROTEIN DELIVERY COMPOSITIONS
AND METHODS OF USE

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED
MAY 06 2002

TECH CENTER 1600/2900

SEQUENCE SUBMISSION STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

APR 26 2002

Technology Center 2600

Dear Sir:


This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed February 22, 2002. I hereby state that the Sequence Listing does not include new matter.

An initial paper copy of the Sequence Listing as required by 37 C.F.R. § 1.821(c) is submitted herewith. A copy of the Sequence Listing in computer readable form as required by 37 C.F.R. § 1.821(e) is submitted herewith. As required by 37 C.F.R. § 1.821(f), I hereby state that the data on the enclosed diskette is identical to the initial paper copy of the Sequence Listing.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 4-19-02

By: 
Ned A. Israelsen
Registration No. 29,655
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(619) 235-8550